

Synthesis of Novel 1-Aryl-9*H*-xanthen-9-ones

Cátia I. C. Esteves,^a Clementina M. M. Santos,^b Cristela M. Brito,^a Artur M. S. Silva,^{*a} José A. S. Cavaleiro^a

^a Department of Chemistry & QOPNA, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal
Fax +351(234)370084; E-mail: artur.silva@ua.pt

^b Department of Vegetal Production and Technology, School of Agriculture, Campus de Santa Apolónia, 5301-855 Bragança, Portugal

Received 28 February 2011

Abstract: A novel route for the synthesis of 1-aryl-9*H*-xanthen-9-ones is reported. This methodology involves the condensation of 2-methylchromone with cinnamaldehydes leading to (*E,E*)-2-(4-arylbuta-1,3-dien-1-yl)-4*H*-chromen-4-ones. The final steps involved electrocyclization and oxidation of the latter compounds, in an one-pot synthesis, giving the desired 1-aryl-9*H*-xanthen-9-ones.

Key words: 1-arylxanthenes, 2-methylchromone, aldol condensation, electrocyclization, oxidation

Xanthenone or 9*H*-xanthen-9-one is the parent compound of an important class of oxygenated heterocycles with a dibenzo- γ -pyrone framework. This heterocyclic system is widespread in nature, commonly distributed in several higher plant families, such as *Gentianaceae*, *Guttiferae*, and *Polygalaceae*, and in a few families of fungi and lichens.¹


Naturally occurring xanthenes present different types of substituents (e.g., hydroxy, methoxy, and prenyl groups) in different positions of their scaffold leading to a large variety of analogues.² The presence of an aryl ring attached to the xanthenone core has only been reported in some synthetic derivatives.^{3–5} In our previous studies we have developed methodologies for the synthesis of xanthenes bearing a 2,3-diaryl substitution pattern but, as far as we are aware, the introduction of a 1-aryl substituent in the xanthenone nucleus has never been reported.⁵

In recent years, several studies have emphasized the biological and pharmacological properties of both natural and synthetic xanthenes,⁶ including anti-inflammatory,⁷ cancer chemopreventive,⁸ antimalarial,⁹ and radical scavenging¹⁰ activities, but also inhibition of cyclooxygenase, cholinesterase, and other enzymes.^{6,11} Some xanthenes even surpass the antimicrobial activity of traditional antibiotics.¹² These promising applications and the restricted chemical xanthenone scaffolds have motivated the search for novel synthetic derivatives and the development of new synthetic routes for 9*H*-xanthen-9-one-type compounds.

The classical methods for the synthesis of xanthenes are based on the formation of key intermediates, such as benzophenones, obtained by a Friedel–Crafts acylation or a Fries rearrangement, or diaryl ethers, prepared by inter-

molecular Ullmann condensation of phenolates with *ortho*-halobenzoic acids or by Smiles rearrangement of diaryl esters. To build more complex structures, several modifications on the traditional methods have been made and a great number of nonconventional approaches have emerged.¹³

In the present communication we report a new strategy for the synthesis of novel 1-aryl-9*H*-xanthen-9-ones **6a–e** (Scheme 1).



Scheme 1 Reagents and conditions: A. (i) MeCOCl, pyridine, r.t., 15 h; (ii) NaH, THF, reflux, 2 h; (iii) DMSO, I₂ (4 h) or *p*-toluenesulfonic acid (2 h), 100 °C; B. (i) dry DMF, Pd(OAc)₂, NBu₄OAc, K₂CO₃, KCl, 90 °C, 2–8 h; (ii) HCl, r.t., 10 min; C. Na, EtOH, r.t. D. 1,2,4-trichlorobenzene, I₂, reflux, 48 h.

The required starting material 2-methylchromone (**2**) was prepared by three-step Baker–Venkataraman sequence,¹⁴ in good overall yields (Scheme 1) involving acetylation of 2'-hydroxyacetophenone (**1**) followed by the base-catalysed Baker–Venkataraman rearrangement¹⁴ of the formed ester, leading to the formation of a 1,3-diketone derivative, which, after cyclodehydration afforded the desired 2-methylchromone (**2**). The last step was carried out with a catalytic amount of *p*-toluenesulfonic acid or iodine in DMSO. The results obtained seem to indicate that the cyclodehydration is favorable in the acidic medium, as previously reported for the synthesis of other chromone-type

compounds.¹⁵ The reaction of aryl bromides or iodides **3** with acrolein diethyl acetal in a palladium-catalyzed coupling reaction provided the required cinnamaldehydes **4b–e** (Scheme 1).¹⁶

The chemical reactivity of 2-methylchromones and further transformation into other biologically active analogues have been the subject of several works.¹⁷ Among them is a number of condensation reactions with carbonyl compounds to afford new heterocyclic systems. For example, 2-styrylchromone derivatives have been synthesized from 2-methylchromones and these even find use as substrates in the preparation of new and remarkably bioactive xanthenes.¹⁰

Focussing on this concept, optimization studies were carried out for the synthesis of the novel (*E,E*)-2-(4-arylbuta-1,3-dien-1-yl)-4*H*-chromen-4-ones **5a–e**. The condensation of 2-methylchromone (**2**) with cinnamaldehydes **4a–e** using sodium methoxide, formed in situ from sodium and methanol, as base was ineffective. After several attempts we concluded that the base, its stoichiometry and the reaction time were very important to provide **5a–e** in good yields (Scheme 1, Table 1). (*E,E*)-2-(4-Arylbuta-1,3-dien-1-yl)-4*H*-chromen-4-ones **5a–e** were thus obtained using four equivalents of base, sodium ethoxide, with the exception of the nitro derivative, which was prepared using only one equivalent of base but with longer reaction time (Table 1).^{18,19}

Table 1 Conditions and Yields Obtained in the Formation of **5a–e** and Yields in the Synthesis of **6a–e**

Entry	Base (equiv)	Time (h)	Yield of 5 (%)	Yield of 6 (%)
1	4	4	5a 80	6a 55
2	4	8	5b 70	6b 56
3	4	4	5c 80	6c 70
4	4	4	5d 77	6d 67
5	1	55	5e 68	6e 50

Subsequently, extensive studies into the electrocyclization and oxidation reactions of (*E,E*)-2-(4-arylbuta-1,3-dien-1-yl)-4*H*-chromen-4-ones **5a–e** were performed. In the first attempt, chromone **5a** was refluxed in 1,2,4-trichlorobenzene but, even after one week, no product was observed. However, when a catalytic amount of iodine was added to the reaction mixture, TLC analysis after 18 hours revealed the presence of three spots; the one with the lowest R_f value corresponding to the unreacted starting material **5a** (44%). The NMR spectra of the other two spots proved that the one with the highest R_f value was the expected 1-phenyl-9*H*-xanthen-9-one **6a** (15%) and the other one as the semioxidized intermediate of the final xanthone, 1,4-dihydro-1-phenyl-9*H*-xanthen-9-one (**7a**, 20%).²⁰ On extending the reaction time to 48 hours only the desired xanthone **6a** was isolated and the best yields were accomplished with these reaction conditions (Scheme 1, Table 1).^{21,22} The extension of these condi-

tions to compounds **5b–e** led to preparation of **6b–e** in good yields (50–70%). An extensive study on the referred electrocyclization and oxidation reactions, involving other solvents, temperature, and reaction time and even with irradiation with a high-pressure UV lamp, did not lead to better yields of **6a–e**.

The initial stereochemistry of the $\alpha,\beta,\gamma,\delta,\epsilon,\zeta$ -unsaturated system (vide infra) of **5a–e** was clearly not appropriate for the ring closure in the attempted thermal electrocyclization, even at higher temperature. However, since it is well known that iodine is an efficient catalyst in the *trans-cis* isomerisation of alkenes,²³ a catalytic amount was enough to initiate reaction. A plausible mechanism for the described transformations invokes a thermal electrocyclization of the $\alpha,\beta,\gamma,\delta,\epsilon,\zeta$ -unsaturated system of **5a–e** followed by a [1,3]-sigmatropic shift to give 1,4-dihydroxanthen-9-ones **7a–e**, which, after in situ oxidation, yield 1-aryl-9*H*-xanthen-9-ones **6a–e**.

All novel compounds synthesized have been characterized by NMR, MS, and elemental analysis. The most important feature in the ¹H NMR spectra of chromones **5a–e** are the singlets corresponding to the resonance of protons H-3, at $\delta_{\text{H}} = 6.24\text{--}6.31$ ppm. Other important characteristics are the ³ $J_{\text{H}\alpha\text{--H}\beta}$ and ³ $J_{\text{H}\gamma\text{--H}\delta}$ values of 15–16 Hz indicating a *trans-trans* configuration for the two vinylic systems. The assignments of vinylic protons and of their stereochemistry were confirmed by HMBC and NOESY spectra. Thus, in the HMBC spectrum of chromones **5a–e** it was possible to observe the connectivity of H- α with C-2 and C-3 and of H- γ and H-3',5' with C-1'. In the NOESY spectra it was possible to observe the close proximity of H- α with H-3 and H- γ and of H- β with H- δ (Figure 1).




Figure 1 Main results obtained in the HMBC (connectivities) and NOESY (close proximity) spectra of compounds **5** and **6**

The main features in the ¹H NMR spectra of 1-aryl-9*H*-xanthen-9-ones **6a–e** are the double doublets corresponding to the protons H-8, resonating at higher frequency values ($\delta_{\text{H}} = 8.15\text{--}8.19$ ppm) due to the anisotropic and

mesomeric deshielding effects of the carbonyl group, and the lowest frequency aromatic signals corresponding to the resonance of protons H-2, at $\delta_{\text{H}} = 7.13\text{--}7.18$ ppm. The structure of xanthenes **6a–e** was also supported by the main connectivities found in their HMBC spectra (Figure 1).

In conclusion, we have established a simple synthetic methodology for preparing 1-aryl-9H-xanthen-9-ones **6a–e**, by the electrocyclization and oxidation reactions of the new (*E,E*)-2-(4-arylbuta-1,3-dien-1-yl)-4H-chromen-4-ones **5a–e**. The latter compounds were obtained by condensation of 2-methylchromone (**2**) with cinnamaldehydes **4a–e**.

Acknowledgment

Thanks are due to the University of Aveiro, 'Fundação para a Ciência e a Tecnologia', and FEDER for funding the Organic Chemistry Research Unit and the Portuguese National NMR Network (RNRMN). One of us (C. I. C. Esteves) is also grateful to FCT for her fellowship (SFRH/BI/51098/2010).

References and Notes

- (1) (a) Hostettman, K.; Hostettman, M. *Plant Phenolics*, In *Methods in Plant Biochemistry*, Vol. 1; Dey, P. M.; Harbone, J. B., Eds.; Academic Press: San Diego, **1989**, 493. (b) Gales, L.; Damas, A. M. *Curr. Med. Chem.* **2005**, *12*, 2499.
- (2) Vieira, L. M. M.; Kijjoa, A. *Curr. Med. Chem.* **2005**, *12*, 2413.
- (3) Fukawa, I.; Yoneda, H.; Asahi, K. K. EP 0237004, **1987**.
- (4) Kelkar, A. S.; Letcher, R. M.; Cheung, K.-K.; Chiu, K.-F.; Brown, G. D. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3732.
- (5) (a) Santos, C. M. M.; Silva, A. M. S.; Cavaleiro, J. A. S. *Eur. J. Org. Chem.* **2009**, 2642. (b) Santos, C. M. M.; Silva, A. M. S.; Cavaleiro, J. A. S. *Synlett* **2007**, 3113. (c) Santos, C. M. M.; Silva, A. M. S.; Cavaleiro, J. A. S. *Synlett* **2005**, 3095.
- (6) (a) El-Seedi, H. R.; El-Barbary, M. A.; El-Ghorab, D. M.; Bohlin, L.; Borg-Karlson, A. K.; Göransson, U.; Verpoorte, R. *Curr. Med. Chem.* **2010**, *17*, 854. (b) Pinto, M. M. M.; Sousa, M. E.; Nascimento, M. S. *J. Curr. Med. Chem.* **2005**, *12*, 2517.
- (7) (a) Park, H. H.; Park, Y.-D.; Han, J.-M.; Im, K.-R.; Lee, B. W.; Jeong, I. Y.; Jeong, T.-S.; Lee, W. S. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5580. (b) Jiang, D.-J.; Dai, Z.; Li, Y.-J. *Cardiovasc. Drug Rev.* **2004**, *22*, 91.
- (8) (a) Na, Y. *J. Pharm. Pharmacol.* **2009**, *61*, 707. (b) Ee, G. C. L.; Daud, S.; Izzaddin, S. A.; Rahmani, M. *J. Asian Nat. Prod. Res.* **2008**, *10*, 475.
- (9) (a) Riscoe, M.; Kelly, J. X.; Winter, R. *Curr. Med. Chem.* **2005**, *12*, 2539. (b) Portela, C.; Afonso, C. M. M.; Pinto, M. M. M.; Ramos, M. J. *Bioorg. Med. Chem.* **2004**, *12*, 3313.
- (10) (a) Santos, C. M. M.; Freitas, M.; Ribeiro, D.; Gomes, A.; Silva, A. M. S.; Cavaleiro, J. A. S.; Fernandes, E. *Bioorg. Med. Chem.* **2010**, *18*, 6776. (b) Pothitirat, W.; Chomnawang, M. T.; Supabphol, R.; Gritsanapan, W. *Fitoterapia* **2009**, *80*, 442.
- (11) Khan, M. T. H.; Orhan, I.; Şenol, F. S.; Kartal, M.; Sener, B.; Dvorská, M.; Šmejkal, K.; Šlapetová, T. *Chem. Biol. Interact.* **2009**, *181*, 383.
- (12) Franklin, G.; Conceição, L. F. R.; Kombrink, E.; Dias, A. C. P. *Phytochemistry* **2009**, *70*, 60.
- (13) Sousa, M. E.; Pinto, M. M. M. *Curr. Med. Chem.* **2005**, *12*, 2447.
- (14) (a) Mahal, H. S.; Venkataraman, K. *J. Chem. Soc.* **1934**, 1767. (b) Baker, W. *J. Chem. Soc.* **1933**, 1381.
- (15) Santos, C. M. M.; Silva, A. M. S.; Cavaleiro, J. A. S. *Eur. J. Org. Chem.* **2003**, 4575.
- (16) Battistuzzi, G.; Cachi, S.; Fabrizi, G. *Org. Lett.* **2003**, *5*, 777.
- (17) Ibrahim, M. A.; Ali, T. E.; Alnamer, Y. A.; Gabr, Y. A. *ARKIVOC* **2010**, (i), 98.
- (18) **Typical Experimental Procedure**
Sodium (0.11 g, 4.8 mmol) was gradually added to dry EtOH (5 mL), and the mixture was stirred until it reached r.t. 2-Methylchromone (**2**, 0.2 g, 1.2 mmol) and the appropriate cinnamaldehyde **4a–e** (1.5 mmol) were added and the reaction mixture allowed to stand at r.t. until complete disappearance of chromone **2** (TLC). The solution was then poured into ice (20 g) and H₂O (30 mL) and adjusted to pH 4 with dilute HCl. The solid was removed by filtration, dissolved in CH₂Cl₂, and purified by silica gel column chromatography using CH₂Cl₂ as eluent. The solvent was evaporated the residue were recrystallized from EtOH to give the (*E,E*)-2-(4-arylbuta-1,3-dien-1-yl)-4H-chromen-4-ones **5a–e** in good yields (Table 1).
- (19) **Physical Data of (*E,E*)-2-[4-(4-methoxyphenyl)buta-1,3-dien-1-yl]-4H-chromen-4-one (**5c**)**
Mp 137–139 °C. ¹H NMR (300,13 MHz, CDCl₃): $\delta = 3.84$ (s, 3 H, OCH₃), 6.24 (s, 1 H, H-3), 6.32 (d, 1 H, *J* = 15.3 Hz, H- α), 6.84–6.87 (m, 1 H, H- δ), 6.90 (d, 2 H, *J* = 8.8 Hz, H-3',5'), 6.90–6.96 (m, 1 H, H- γ), 7.38 (ddd, 1 H, *J* = 8.2, 7.1, 0.9 Hz, H-6), 7.41–7.44 (m, 1 H, H- β), 7.43 (d, 2 H, *J* = 8.8 Hz, H-2',6'), 7.49 (d, 1 H, *J* = 8.1 Hz, H-8), 7.67 (ddd, 1 H, *J* = 8.1, 7.1, 1.7 Hz, H-7), 8.18 (dd, 1 H, *J* = 8.2, 1.7 Hz, H-5). ¹³C NMR (75.47 MHz, CDCl₃): $\delta = 55.3$ (OCH₃), 109.9 (C-3), 114.3 (C-3'-5'), 117.7 (C-8), 122.3 (C- α), 124.1 (C-10), 124.8 (C-6), 125.0 (C- γ), 125.5 (C-5), 128.5 (C-2',6'), 128.6 (C-1'), 133.6 (C-7), 137.8 (C- β), 138.9 (C- δ), 140.4 (C-9), 160.3 (C-4'), 162.0 (C-2), 178.4 (C-4). ESI-MS: *m/z* (rel. int.) = 305 (100) [M + H]⁺, 327 (110) [M + Na]⁺, 343 (20) [M + K]⁺, 631 (11) [2 M + Na]⁺. Anal. Calcd for C₂₀H₁₆O₃: C, 78.93; H, 5.30. Found: C, 78.86; H, 5.30.
- (20) **Physical Data of 1,4-Dihydro-1-phenyl-9H-xanthen-9-one (**7a**)**
Yellow oil. ¹H NMR (300.13 MHz, CDCl₃): $\delta = 2.76$ (ddd, 1 H, *J* = 18.6, 5.8, 1.3 Hz, H-4_{trans}), 3.01 (ddd, 1 H, *J* = 18.6, 9.7, 2.8 Hz, H-4_{cis}), 4.56 (d, 1 H, *J* = 9.7 Hz, H-1), 6.39 (dd, 1 H, *J* = 9.7, 2.8 Hz, H-2), 6.44–6.51 (m, 1 H, H-3), 7.14–7.26 (m, 3 H, H-3',4',5'), 7.33–7.35 (m, 2 H, H-2',6'), 7.33–7.37 (m, 1 H, H-7), 7.45 (d, 1 H, *J* = 7.9 Hz, H-5), 7.62 (ddd, 1 H, *J* = 7.9, 7.7, 1.6 Hz, H-6), 8.17 (dd, 1 H, *J* = 7.9, 1.6 Hz, H-8). ¹³C NMR (75.47 MHz, CDCl₃): $\delta = 31.5$ (C-4), 33.4 (C-1), 116.6 (C-9b), 117.9 (C-5), 121.9 (C-2), 124.3 (C-8a), 124.8 (C-7), 125.9 (C-8), 125.9 (C-4'), 127.1 (C-2',6'), 128.4 (C-3',5'), 133.1 (C-6), 138.4 (C-3), 143.3 (C-1'), 155.4 (C-4b), 159.3 (C-4a), 176.4 (C-9).
- (21) **Typical Experimental Procedure**
Iodine (18 mg, 0.07 mmol) was added to a solution of the appropriated chromone **5a–e** (0.35 mmol) in 1,2,4-trichlorobenzene (5 mL), and the mixture was refluxed for 48 h. After this period the solution was directly purified by silica gel column chromatography using light PE as eluent to remove 1,2,4-trichlorobenzene and then CH₂Cl₂ to recover the product. The solvent was evaporated to dryness and the residue were recrystallized from EtOH to give the 1-aryl-9H-xanthen-9-ones **6a–e** in moderated yields (Table 1).

(22) **Physical Data of 1-Phenyl-9H-xanthen-9-one (6a)**

Mp 177–179 °C. ¹H NMR (300.13 MHz, CDCl₃): δ = 7.18 (dd, 1 H, *J* = 7.2, 1.2 Hz, H-2), 7.31 (ddd, 1 H, *J* = 7.8, 7.5, 1.1 Hz, H-7), 7.33–7.36 (m, 2 H, H-2',6'), 7.41–7.45 (m, 3 H, H-3',4',5'), 7.48 (d, 1 H, *J* = 8.6 Hz, H-5), 7.53 (dd, 1 H, *J* = 8.4, 1.2 Hz, H-4), 7.67–7.80 (m, 2 H, H-3 and H-6), 8.18 (dd, 1 H, *J* = 7.8, 1.7 Hz, H-8). ¹³C NMR (75.47 MHz, CDCl₃): δ = 117.4 (C-5), 117.7 (C-4), 119.3 (C-9b), 122.7 (C-8a), 123.8 (C-7), 127.0 (C-8), 127.1 (C-4'), 127.2 (C-2),

127.5 (C-3',5'), 128.4 (C-2',6'), 133.4 (C-3), 134.5 (C-6), 141.8 (C-1'), 144.2 (C-1), 155.4 (C-4b), 157.3 (C-4a), 176.9 (C-9). ESI-MS: *m/z* (rel. int.) = 273 (100) [M + H]⁺, 295 (76) [M + Na]⁺, 311 (12) [[M + K]⁺, 567 (4) [2 M + Na]⁺. Anal. Calcd for C₁₉H₁₂O₂: C, 83.81; H, 4.44. Found: C, 83.57; H, 4.13.

(23) Hepperle, S. S.; Li, Q.; East, A. L. L. *J. Phys. Chem. A* **2005**, *109*, 10975.